F98 Company Report

Analyst Coverage

Research analysts covering F98.

Recent press releases and 8-K filings for F98.

CytoMed Therapeutics Reports H1 2025 Financial Results and Pipeline Progress

F98

Earnings

New Projects/Investments

Revenue Acceleration/Inflection

CytoMed Therapeutics reported a 100% increase in revenue to SGD 156,000 for the six months ended June 30, 2025, primarily from new private-block banking services.
The company recorded a net loss of SGD 2.25 million and a loss per share of SGD 0.19 for H1 2025.
As of June 30, 2025, cash and bank balances stood at SGD 2.86 million, a decrease from SGD 4.97 million at December 31, 2024.
Key pipeline updates include completing dose level one for CTM-N2D in June 2025 and an ongoing IND application for CTM-GDT.
In August, the company signed an agreement with Levity to raise up to $4.3 million and is rebranding its cord blood banking business as Longevity Bank.

Oct 2, 2025, 2:00 PM

CytoMed Therapeutics Reports H1 2025 Financial Results and Pipeline Updates

F98

Earnings

New Projects/Investments

CytoMed Therapeutics reported revenue of SGD 156,000 for the six months ended June 30, 2025, representing a 100% increase year-on-year, primarily from private blood banking services. The company recorded a net loss of SGD 2.25 million and a loss per share of SGD 0.19 for the same period.
As of June 30, 2025, the company's cash and bank balances stood at SGD 2.86 million and its Net Tangible Assets (NTA) were SGD 7.15 million. This indicates a decrease from SGD 4.97 million in cash and SGD 8.95 million in NTA as of December 31, 2024.
In pipeline developments, the CTM-N2D project completed dose level one in June 2025 and is progressing to dose level two, with a target to complete the phase one trial in 2026. Additionally, a collaboration with MD Anderson Cancer Center on preclinical studies for CTM-GDT was published in a peer-reviewed journal in September 2025.
The company signed an ATM agreement with Levity in August to raise up to $4.3 million and is rebranding its cord blood banking business as LongevityBank.